Topic:

April 2021

In July 2021, GSK received authorization under Health Canada’s Interim Order for Sotrovimab

In July 2021, GSK received authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents. To read more please visit https://ca.gsk.com/en-ca/media/press-releases/gsk-receives-authorization-under-health-canada-s-interim-order-for-sotrovimab-for-injection-to-treat-covid-19-in-high-risk-adults-and-adolescents/

GSK also announced on January 6th that the Government of Canada has purchased additional doses: https://ca.gsk.com/en-ca/media/press-releases/gsk-announces-additional-purchase-agreements-with-the-government-of-canada-for-covid-19-monoclonal-antibody-therapy-sotrovimab/

Lupus Blog Articles:

Nuvaxovid in Canada: How to Access the COVID-19 Vaccine

Read

The Lupus Canada Annual General Meeting 2026

Read

Lupus Canada Impact Report 2025 | Advocacy, Awareness & Research Outcomes

Read